To link to the entire object, paste this link in email, IM or documentTo embed the entire object, paste this HTML in websiteTo link to this page, paste this link in email, IM or documentTo embed this page, paste this HTML in website

ESTROGEN REGULATION OF BIOENERGETICS AND
MITOCHONDRIAL FUNCTION:
IMPLICATIONS FOR ALZHEIMER’S DISEASE RISK AND THERAPEUTICS
by
Jia Yao
A Dissertation Presented to the
FACULTY OF THE USC GRADUATE SCHOOL
UNIVERSITY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
DOCTOR OF PHILOSOPHY
(MOLECULAR PHARMACOLOGY AND TOXICOLOGY)
May 2010
Copyright 2010 Jia Yao

Presented here are a collection of studies that build on our existing knowledge of estrogen actions on brain mitochondria. Previous studies from our lab as well as other colleagues have demonstrated that estrogen (E2, 17β-estradiol) is neuroprotective against neurotoxic insults including exposure to glutamate and amyloid beta (Aβ) (Nilsen et al, 2006; Simpkins and Dykens, 2007; Vina et al, 2007b). Further, the E2 induced neuroprotective mechanisms converge on mitochondria (Brinton, 2008b; Nilsen and Diaz Brinton, 2003; Nilsen et al, 2007). In the current research project, we have hypothesized that mitochondria, particularly mitochondrial bioenergetics play a pivotal role in the pathogenesis of age-related Alzheimer’s disease (AD) whereas estrogen proactively sustains and enhances mitochondrial function that was compromised in aging and AD. To test our hypotheses, we have conducted a combination of in vitro and in vivo analyses which address four specific aims. Specific Aim 1 (Chapter 2) serves to investigate the role of mitochondrial bioenergetic deficits in AD pathogenesis using the triple transgenic Alzheimer’s mouse model. Specific Aim 2 (Chapter 3) serves to determine the impact of E2 deficiency on mitochondrial function and AD progression. Specific Aim 3 (Chapter 4) seeks to investigate the underlying mechanism of estrogen induced neuroprotection as well as to examine the role of different estrogen receptors in estrogen action in the brain. Specific Aim 4 (Chapter 5) focuses on the therapeutic implications of the findings from the previous three aims and introduces a novel therapeutic strategy targeting mitochondria for preventing AD and/or delaying the progression of AD.; Data from these four specific aims have demonstrated that: 1) Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in the 3xTgAD mouse model. 2) Loss of ovarian hormones either due to age-related reproductive senescence or surgical ovariectomy (OVX) significantly exacerbates mitochondrial dysfunction that occurs in aging or AD. 3) E2 treatment initiated at the time of OVX prevented the OVX-induced mitochondrial deficits by sustaining mitochondrial bioenergetic capacity, decreasing oxidative stress, and preventing mitochondrial amyloid and ABAD induction. 4) Therapeutic strategies targeting mitochondria could alter AD progression by manipulating brain mitochondrial bioenergetic profile.; We believe that findings from these studies will expand our understanding of the mechanism of AD pathogenesis as well as the pharmacological pathway of estrogen induced neuroprotection against AD. Our research will also enable the development of novel therapeutics that target mitochondrial bioenergetics for the prevention and treatment of AD and other neurodegenerative diseases that could be partially attributed to mitochondrial dysfunction.

ESTROGEN REGULATION OF BIOENERGETICS AND
MITOCHONDRIAL FUNCTION:
IMPLICATIONS FOR ALZHEIMER’S DISEASE RISK AND THERAPEUTICS
by
Jia Yao
A Dissertation Presented to the
FACULTY OF THE USC GRADUATE SCHOOL
UNIVERSITY OF SOUTHERN CALIFORNIA
In Partial Fulfillment of the
Requirements for the Degree
DOCTOR OF PHILOSOPHY
(MOLECULAR PHARMACOLOGY AND TOXICOLOGY)
May 2010
Copyright 2010 Jia Yao